In the EMILIA study involving HER2-positive advanced breast cancer patients, T-DM1 extended the median PFS to 9.6 months and the OS to 30.9 months, and resulted in milder adverse events than that observed with the combination of lapatinib and capecitabine (97–99). Here, ERBB2 is linked to breast carcinoma.